Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C.E.R.A. maintenance in chronic renal anemia
NCT00642304Phase 3Completed
- Sponsor
- Roche
- Start
- Mar 2008
- Primary completion
- Dec 2009
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of methoxy polyethylene glycol-epoetin beta in anemia of chronic kidney disease (CKD-A), sponsored by Roche. Primary endpoint: Percentage of Participants Maintaining Hb Concentration Within +/-1 g/dL of Reference and Between 10.5 to 12.5 g/dL. Started Mar 2008; status: completed.
02
Drugs
methoxy polyethylene glycol-epoetin beta
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT00642304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00642304.